Please Wait

Applying Filters...

Global API micronization market set to surge 49% by 2030, led by specialized industry pioneers

Data Compilation
#PharmaFlow

Pipeline Prospector August 2025: Novo’s Wegovy approved for MASH, Tonix Pharma’s fibromyalgia drug okayed

Stock Recap
#PipelineProspector

Glycopyrrolate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

64 API Suppliers, 22 USDMF, 9 CEP/COS, 2 JDMF, 7 EU WC, 7 KDMF, 21 NDC API, 36 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

212 Drugs in Development

212 Drugs in Development

FINISHED DOSAGE FORMULATIONS

156 FDF Dossiers, 88 FDA Orange Book, 22 Europe, 13 Canada, 2 Australia, 7 South Africa, 24 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 1MG, TABLET;ORAL - 2MG, INJECTABLE;INJECTION - 0.2MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, POWDER;INHALATION - 15.6MCG/INH, POWDER;INHALATION - 15.6MCG/INH;27.5MCG/INH, SOLUTION;INHALATION - 25MCG/ML, TABLET, ORALLY DISINTEGRATING;ORAL - 1.7MG, TABLET;ORAL - 1MG, TABLET;ORAL - 2MG, INJECTABLE;INJECTION - 0.2MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, POWDER;INHALATION - 15.6MCG/INH, POWDER;INHALATION - 15.6MCG/INH;27.5MCG/INH, SOLUTION;INHALATION - 25MCG/ML, TABLET, ORALLY DISINTEGRATING;ORAL - 1.7MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 2 Rochem International Inc, 6 SPI Pharma, 1 DKSH, 4 Boai NKY Pharmaceuticals Ltd, 5 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 4 Kirsch Pharma, 8 Actylis, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 10 BASF, 1 CD Formulation, 6 DFE Pharma, 3 Finar, 5 Gangwal Chemicals, 1 Ideal Cures, 3 Ingredion Pharma Solutions, 16 Kerry, 2 Keval Exports, 12 Microlex e.U, 1 Nippon Fine Chemical, 2 Nitika Pharmaceutical Specialities, 1 Novo Excipients, 3 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 26 Roquette, 1 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 9 Sigachi Industries, 3 Silverline Chemicals, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

54 Fillers, Diluents & Binders, 27 Direct Compression, 21 Granulation, 20 Parenteral, 17 Disintegrants & Superdisintegrants, 15 Thickeners and Stabilizers, 14 Film Formers & Plasticizers, 13 Co-Processed Excipients, 12 Taste Masking, 11 Lubricants & Glidants, 10 Solubilizers, 9 Chewable & Orodispersible Aids, 8 Coating Systems & Additives, 7 Topical, 7 Controlled & Modified Release, 3 Emulsifying Agents, 1 Soft Gelatin, 1 API Stability Enhancers, 1 Surfactant & Foaming Agents, 1 Rheology Modifiers, 1 Dry Powder Inhalation

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 1 Stock Recap #PipelineProspector, 116 News #PharmaBuzz

GLOBAL SALES INFORMATION

32 US Medicaid Prescriptions, 27 Regulatory FDF Prices, 59 Annual Reports

MARKET PLACE

24 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

31 US Patents, 19 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 21 Others

$ Xls

Filters

$PRINCIPAL DISPLAY PANEL\nNDC 59630-205-10 100 Tablets\nROBINULÂ® FORTE\n(glycopyrrolate tablets, USP)\n2 mg\n$

TABLET;ORAL - 2MG

$PRINCIPAL DISPLAY PANEL\nNDC 59630-200-10 100 Tablets\nROBINULÂ®\n(glycopyrrolate tablets, USP)\n1 mg\n$

TABLET;ORAL - 1MG

INJECTABLE;INJECTION - 0.2MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

POWDER;INHALATION - 15.6MCG/INH

TABLET, ORALLY DISINTEGRATING;ORAL - 1.7MG

POWDER;INHALATION - 15.6MCG/INH;27.5MCG/INH

SOLUTION;INHALATION - 25MCG/ML

X

Contact us
to update this info

Glycopyrrolate

Glycopyrrolate

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

64 API Suppliers

22 USDMF

9 CEP/COS

2 JDMF

7 EU WC

7 KDMF

21 NDC API

36 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

212 Drugs in Development

FINISHED DOSAGE FORMULATIONS

156 FDF Dossiers

88 FDA Orange Book

22 Europe

13 Canada

2 Australia

7 South Africa

24 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 1MG

TABLET;ORAL - 2MG

INJECTABLE;INJECTION - 0.2MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

POWDER;INHALATION - 15.6MCG/INH

POWDER;INHALATION - 15.6MCG/INH;27.5MCG/INH

SOLUTION;INHALATION - 25MCG/ML

TABLET, ORALLY DISINTEGRATING;ORAL - 1.7MG

TABLET;ORAL - 1MG

TABLET;ORAL - 2MG

INJECTABLE;INJECTION - 0.2MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

POWDER;INHALATION - 15.6MCG/INH

POWDER;INHALATION - 15.6MCG/INH;27.5MCG/INH

SOLUTION;INHALATION - 25MCG/ML

TABLET, ORALLY DISINTEGRATING;ORAL - 1.7MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI

2 Rochem International Inc

6 SPI Pharma

1 DKSH

4 Boai NKY Pharmaceuticals Ltd

5 Gangwal Healthcare

4 Nanjing Well Pharmaceutical

4 Kirsch Pharma

8 Actylis

4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Ashland

10 BASF

1 CD Formulation

6 DFE Pharma

3 Finar

5 Gangwal Chemicals

1 Ideal Cures

3 Ingredion Pharma Solutions

16 Kerry

2 Keval Exports

12 Microlex e.U

1 Nippon Fine Chemical

2 Nitika Pharmaceutical Specialities

1 Novo Excipients

3 Pharmatrans-Sanaq

5 Pluviaendo

3 Prachin Chemical

26 Roquette

1 Seppic

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

9 Sigachi Industries

3 Silverline Chemicals

1 Ulanqab Kema New Material

1 Valens Pharmachem

3 Vasa Pharmachem

1 Zhejiang Huakang Pharmaceutical

INJECTABLE;INJECTION - 0.2MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - 0.2MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons